Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
211At-anti-CD44v6 VHH dimer
- Development stage
- Preclinical
- Lead developer
- Sichuan University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intralesional
01
Overview
211At-anti-CD44v6 VHH dimer is a preclinical-stage targeted alpha-particle radiopharmaceutical being developed by West China Hospital of Sichuan University. It consists of a CD44v6-specific single-domain antibody (VHH) dimer conjugated with the alpha-emitting radionuclide astatine-211 (211At). The therapeutic is designed for local intrapleural administration to treat malignant pleural effusion (MPE) in lung adenocarcinoma (LUAD). It specifically targets and depletes SPP1+/CD44v6+ tumor-associated macrophages (TAMs) in the immunosuppressive tumor microenvironment. By selectively inducing DNA double-strand breaks and immunogenic cell death (ICD) in these TAMs, the agent triggers cGAS-STING pathway activation and subsequent CD8+ T-cell-mediated antitumor immunity.
- Other names
- 211At-labeled anti-CD44v6 VHH dimerastatine-211-labeled anti-CD44v6 VHH dimerastatine211-labeled anti-CD44v6 VHH dimerastatine 211-labeled anti-CD44v6 VHH dimer
02
Targets
CD44v6 (CD44 variant isoform 6)DNACD44 (CD44 antigen)
Beyond the preview
Go deeper on 211At-anti-CD44v6 VHH dimer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 211At-anti-CD44v6 VHH dimer.